FDA approves new CRC drug

Lonsurf, a combination of trifluridine and tipiracil in pill form, is designed to treat advanced colorectal cancer patients who have had previous chemotherapy and biologic treatments. The drug has now received FDA approval, according to the American Gastroenterological Association.

Advertisement
Carrie Pallardy

Lonsurf’s efficacy was analyzed in a double-blind study, according to the report. Patients receiving the newly-approved drug lived an average of 7.1 months, while patients treated with a placebo lived an average of 5.3 months.

More articles on gastroenterology:
5 recent GI study findings to know
New drug shows potential in fighting C. diff: 4 notes
10 of the biggest GI/endoscopy stories in 2015

Accelerate smarter care: Powering Efficiency and Innovation Across Modern Care

Recommended OnDemand Webinar

Advertisement

Next Up in GI & Endoscopy

  • GIs sound the alarm on CMS payment changes

    Gastroenterologists are raising concerns about the CMS’ finalized payment policies, according to a joint statement from the American College of…

    By: Patsy Newitt

  • The new frontiers in GI care

    As gastroenterology evolves, leaders are reimagining how to deliver comprehensive, patient-centered care.  Dinesh Madhok, MD, CEO of Jacksonville, Fla.-based Borland…

    By: Patsy Newitt
Advertisement

Comments are closed.